Marshall Wace
NVO

Marshall Wace’s Novo Nordisk NVO Stock Holding History

Marshall Wace’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-130,000
Closed -$8.97M – 3246
2025
Q2 		$8.97M Buy
+130,000
New +$8.84M 0.01% 886

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Marshall Wace's NVO Position: Q1 2026 in Review

Marshall Wace increased its Novo Nordisk (NVO) stake by 459% in Q1 2026, buying an estimated $119M and bringing the position to 3,046,611 shares worth $112M. The position accounts for 0.11% of the portfolio, ranked #149.

Marshall Wace first reported a position in NVO in Q3 2015 and has held it in 21 quarters since. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Marshall Wace held 3,046,611 shares of Novo Nordisk worth $112M as of Q1 2026.
  • Marshall Wace bought 2,502,064 Novo Nordisk shares in Q1 2026, an estimated $119M.
  • Novo Nordisk made up 0.11% of Marshall Wace's portfolio in Q1 2026, its #149 holding.
  • Marshall Wace first reported a position in Novo Nordisk in Q3 2015 and has held it in 21 quarters since.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.